IP Library Granted Patent US 8,952,171
Granted Patent B2
US 8,952,171 · App. 13/815,735 · Granted Feb 10, 2015

Compounds and uses thereof for the modulation of hemoglobin

Inventors: Qing Xu (South San Francisco, CA); Zhe Li (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D271/16C07D207/08C07D207/34C07D211/22C07D211/60C07D211/78C07D213/81C07D241/04C07D265/30C07D279/12C07D309/08C07D309/28C07D333/38C07D335/02C07D401/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,952,171
App. No.
13/815,735
Granted
Feb 10, 2015
Kind
B2
Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

Claims (45)

1. A compound of Formula (I-i):

or a tautomer thereof, or pharmaceutically acceptable salt of each thereof,

wherein

R 3 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 4 -C 6 alkoxy, C 3 -C 8 cycloalkoxy, or —NR 1 R 2 ;

each R 1 and R 2 independently is hydrogen, C 1 -C 6 alkyl, and C 3 -C 8 cycloalkyl, wherein each cycloalkyl, is optionally substituted with 1-3 C 1 -C 6 alkyl groups, or R 1 and R 2 together with the nitrogen atom they are attached to form a 4-7 membered heterocycle optionally substituted with 1-3 C 1 -C 6 alkyl groups;

ring B is phenyl, 5-6 membered heteroaryl having 1-3 nitrogen atoms or oxidized forms of N, or 5-6 membered heterocycle containing up to 2 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S, and oxidized forms of N and S, and wherein the phenyl, 5-6 membered heteroaryl having 1-3 nitrogen atoms or oxidized forms of N, or 5-6 membered heterocycle is optionally substituted with 1-3: halo, C 1 -C 6 alkyl, COR 15 , or COOR 15 ;

R 15 is C 1 -C 6 alkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl or a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S, and oxidized forms of N and S, wherein the alkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with 1-3 C 1 -C 6 alkyl groups;

each V and Z is independently CR 10 R 11 , O, S, SO, SO 2 , or NR 12 ; each R 10 and R 11 independently is hydrogen or C 1 -C 3 alkyl optionally substituted with 1-3 halo, OH, or C 1 -C 6 alkoxy, or CR 10 R 11 is C═O, provided that if one of Y and Z is O, S, SO, SO 2 , then the other is not CO, and Y and Z are not both heteroatoms or oxidized forms thereof;

wherein Y is α or β substituted relative to the —COR 3 ;

R 4 is OH, halo, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkoxy or O—R, where O—R is a phosphate or a carboxylate ester, wherein the C 1 -C 6 alkoxy is optionally substituted with 1-5 halo;

R 6 is halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo, and

p is 0, 1, 2, or 3.

2. A compound of claim 1 wherein Y—Z is —CH 2 O— or —CH 2 CH 2 —.

3. The compound of claim 1 , of Formula IIIA:

wherein ring B is an optionally substituted phenyl or optionally substituted 5-6 membered heteroaryl having 1-3 nitrogen atoms or oxidized forms of N;

R 5 is hydrogen or C 1 -C 6 alkyl, or −OR 5 is a phosphate or a carboxylate ester; and

R 3 , p, Y, Z, and R 6 are defined as in claim 1 .

4. The compound of claim 1 , wherein the compound is of Formula IIIB, IIIC, or IIID:

wherein

are optionally substituted 5-6 membered heterocycle as defined in claim 1 ;

R 5 is hydrogen or C 1 -C 6 alkyl or —OR 5 is a phosphate or a carboxylate; and

R 3 , p, Y, Z, and R 6 are defined as in claim 1 .

5. A compound selected from the group consisting of

or an N oxide thereof, wherein

is a single or a double bond;

each P and Q is independently selected from CHR 17 , NCOR 15 , NCO 2 R 15 ; N—O, O, S, SO, and SO 2 ;

each R 1 and R 2 independently is hydrogen, C 1 -C 6 alkyl, a C 6 -C 10 aryl, 5-10 membered heteroaryl or a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S, and oxidized forms of N and S, wherein the alkyl, aryl, heteroaryl or heterocyclyl is optionally substituted;

R 15 is C 1 -C 6 alkyl, C 6 -C 10 aryl, 5-10 membered heteroaryl or a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S, and oxidized forms of N and S, wherein the alkyl, aryl, heteroaryl or heterocyclyl is optionally substituted;

R 17 is hydrogen or C 1 -C 6 alkyl;

and r is 0, 1, or 2.

6. A compound of formula:

or an N oxide thereof, or a pharmaceutically acceptable salt of each thereof, wherein is a single or a double bond.

7. A composition comprising a compound of claim 1 and at least one pharmaceutically acceptable excipient.

8. The compound of claim 1 , wherein R 3 is C 1 -C 6 alkyl.

9. The compound of claim 1 , wherein R 3 is C 3 -C 8 cycloalkyl.

10. The compound of claim 1 , wherein R 3 is C 4 -C 6 alkoxy.

11. The compound of claim 1 , wherein R 3 is C 3 -C 8 cycloalkoxy.

12. The compound of claim 1 , wherein R 3 is —NR 1 R 2 .

13. A composition comprising a compound of claim 5 and at least one pharmaceutically acceptable excipient.

14. A composition comprising a compound of claim 6 and at least one pharmaceutically acceptable excipient.

15. A composition comprising a compound of claim 8 and at least one pharmaceutically acceptable excipient.

16. A composition comprising a compound of claim 9 and at least one pharmaceutically acceptable excipient.

17. A composition comprising a compound of claim 10 and at least one pharmaceutically acceptable excipient.

18. A composition comprising a compound of claim 11 and at least one pharmaceutically acceptable excipient.

19. A composition comprising a compound of claim 12 and at least one pharmaceutically acceptable excipient.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2013
From: XU, QING; LI, ZHE
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 031438/0490 →
Continuity (1)
Related Publication 20140275008A1 · Sep 18, 2014